Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000145) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
BiTE Eluvixtamab
|
|||||
| Synonyms |
AMG330; AMG 330
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase I | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS018 | [1] , [2] | ||||
| Scaffold Name | BiTE | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Inhibitor | Acute myeloid leukaemia [ICD-11: XH8AA5] | N.A. | Amgen | [1] , [2] | |
| Myeloid cell surface antigen CD33 | Inhibitor | Acute myeloid leukaemia [ICD-11: XH8AA5] | N.A. | Amgen | [1] , [2] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT02520427 | Click to show the Detail | |||||
| Indication | Myeloid Malignancies | |||||
| Phase | Phase I | |||||
| Title | A Phase I First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Myeloid Malignancies | |||||
| Status | Recruiting | |||||
| Sponsor | Amgen | |||||
| NCT04478695 | Click to show the Detail | |||||
| Indication | Relapsed or Refractory Acute Myeloid Leukemia | |||||
| Phase | Phase I | |||||
| Title | A Phase Ib Study Assessing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 330 cIV in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Acute Myeloid Leukemia | |||||
| Status | Terminated (Business Decision) | |||||
| Sponsor | Amgen | |||||